Other
Shoulder Impingement Syndrome
8
Pipeline Programs↗
1
Active Trials↗
4
Companies Involved↗
Shoulder Impingement Syndrome is an early-stage landscape with 8 programs across 4 companies. The most active players are ZARS Pharma Inc., Roche, Milestone Pharmaceuticals Inc.. 3 therapies are approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical3
Phase 1
No programs
Phase 3
No programs
Analysis
Trial Status
8
clinical trials
Completed5 · 63%
Unknown status1 · 13%
Withdrawn1 · 13%
Recruiting1 · 13%
Clinical Trials
Trial Activity
8 trials
Comparison of the Effectiveness of the Ultrasound Guided Injections in Patients With Shoulder Impingement Syndrome
Completed·—·Phase 4·NCT05015322·88 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)